Seeing Is Believing
Currently out of the existing stock ratings of Alan Carr, 57 are a BUY (95%), 2 are a SELL (3.33%), 1 are a HOLD (1.67%).
Analyst Alan Carr works with a stock forecast success ratio of 60.69% fulfilled within 226.82 days on average.
Alan Carr’s has documented 136 price targets and ratings displayed on 18 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on CRSP, Crispr Therapeutics AG at 13-May-2022.
Analyst best performing recommendations are on BHVN (BIOHAVEN PHARMACEUTICAL HOLDING CO LTD).
The best stock recommendation documented was for CARA (CARA THERAPEUTIC) at 2/27/2014. The price target of $22 was fulfilled within 6 days with a profit of $4.64 (26.73%) receiving and performance score of 44.55.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Sell
48
$-22.16 (-31.58%)
42
1 months 2 days ago
3/6 (50%)
$-38.06 (-44.22%)
144
Hold
80
$9.84 (14.03%)
61
1 months 6 days ago
9/12 (75%)
$-6.19 (-7.18%)
109
Buy
112
$41.84 (59.64%)
110
1 months 6 days ago
3/10 (30%)
$25.81 (29.95%)
27
Hold
66
$-4.16 (-5.93%)
57
1 months 6 days ago
4/8 (50%)
$-20.19 (-23.42%)
283
Hold
70
$-0.16 (-0.23%)
110
1 months 6 days ago
3/4 (75%)
$-16.19 (-18.78%)
225
What Year was the first public recommendation made by Alan Carr?